Interpace Biosciences, Inc. (IDXG)
USD 2.41
(-9.06%)
USD 2.41
(-9.06%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 2.8 Million USD | 173.2% |
| 2022 | -3.84 Million USD | 67.28% |
| 2021 | -11.73 Million USD | 55.8% |
| 2020 | -26.55 Million USD | -10.96% |
| 2019 | -23.93 Million USD | -97.48% |
| 2018 | -12.11 Million USD | -92.58% |
| 2017 | -6.29 Million USD | 2.31% |
| 2016 | -6.44 Million USD | 84.06% |
| 2015 | -40.4 Million USD | -199.99% |
| 2014 | -13.47 Million USD | -214.94% |
| 2013 | -4.27 Million USD | 83.05% |
| 2012 | -25.23 Million USD | -436.62% |
| 2011 | -4.7 Million USD | -9.22% |
| 2010 | -4.3 Million USD | 89.39% |
| 2009 | -40.57 Million USD | -11.39% |
| 2008 | -36.42 Million USD | -155.09% |
| 2007 | -14.28 Million USD | -341.5% |
| 2006 | 5.91 Million USD | 121.99% |
| 2005 | -26.88 Million USD | -176.4% |
| 2004 | 35.19 Million USD | 79.64% |
| 2003 | 19.59 Million USD | 139.04% |
| 2002 | -50.17 Million USD | -494.92% |
| 2001 | 12.7 Million USD | -68.92% |
| 2000 | 40.87 Million USD | 160.36% |
| 1999 | 15.7 Million USD | 70.65% |
| 1998 | 9.2 Million USD | 283.33% |
| 1997 | 2.4 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | 874 Thousand USD | -33.74% |
| 2024 Q2 | 2.25 Million USD | 158.24% |
| 2024 Q3 | 1.9 Million USD | -15.6% |
| 2023 Q4 | 1.31 Million USD | 8343.75% |
| 2023 Q2 | 832 Thousand USD | 23.26% |
| 2023 Q3 | -16 Thousand USD | -101.92% |
| 2023 Q1 | 675 Thousand USD | 375.35% |
| 2023 FY | 2.81 Million USD | 173.2% |
| 2022 Q4 | 142 Thousand USD | 118.21% |
| 2022 FY | -3.84 Million USD | 67.28% |
| 2022 Q1 | -1.94 Million USD | 40.54% |
| 2022 Q2 | -3.98 Million USD | -104.41% |
| 2022 Q3 | -780 Thousand USD | 80.41% |
| 2021 Q1 | -3.81 Million USD | 51.93% |
| 2021 FY | -11.73 Million USD | 55.8% |
| 2021 Q3 | -4 Million USD | -37.68% |
| 2021 Q2 | -2.9 Million USD | 23.83% |
| 2021 Q4 | -3.27 Million USD | 18.12% |
| 2020 Q2 | -5.68 Million USD | 7.07% |
| 2020 Q4 | -7.93 Million USD | -32.16% |
| 2020 Q3 | -6 Million USD | -5.57% |
| 2020 Q1 | -6.12 Million USD | 43.5% |
| 2020 FY | -26.55 Million USD | -10.96% |
| 2019 FY | -23.93 Million USD | -97.48% |
| 2019 Q1 | -3.27 Million USD | 27.33% |
| 2019 Q2 | -5.26 Million USD | -60.65% |
| 2019 Q3 | -7.04 Million USD | -33.94% |
| 2019 Q4 | -10.83 Million USD | -53.7% |
| 2018 Q2 | -1.89 Million USD | 41.56% |
| 2018 FY | -12.11 Million USD | -92.58% |
| 2018 Q4 | -4.5 Million USD | -82.88% |
| 2018 Q3 | -2.46 Million USD | -29.87% |
| 2018 Q1 | -3.24 Million USD | 1.52% |
| 2017 FY | -6.29 Million USD | 2.31% |
| 2017 Q4 | -3.29 Million USD | -6.56% |
| 2017 Q3 | -3.09 Million USD | 13.98% |
| 2017 Q1 | 3.69 Million USD | -45.13% |
| 2017 Q2 | -3.59 Million USD | -197.3% |
| 2016 Q2 | -2.89 Million USD | 23.84% |
| 2016 Q1 | -3.8 Million USD | 86.22% |
| 2016 Q4 | 6.74 Million USD | 203.88% |
| 2016 FY | -6.44 Million USD | 84.06% |
| 2016 Q3 | -6.48 Million USD | -124.19% |
| 2015 Q4 | -27.58 Million USD | -589.11% |
| 2015 FY | -40.4 Million USD | -199.99% |
| 2015 Q1 | -2.88 Million USD | 44.86% |
| 2015 Q2 | -5.93 Million USD | -106.04% |
| 2015 Q3 | -4 Million USD | 32.59% |
| 2014 FY | -13.47 Million USD | -214.94% |
| 2014 Q3 | -4.22 Million USD | -67.38% |
| 2014 Q4 | -5.22 Million USD | -23.77% |
| 2014 Q2 | -2.52 Million USD | -68.54% |
| 2014 Q1 | -1.49 Million USD | 58.77% |
| 2013 Q3 | -2.05 Million USD | -142.27% |
| 2013 Q1 | 2.25 Million USD | 109.41% |
| 2013 Q2 | -847 Thousand USD | -137.59% |
| 2013 Q4 | -3.63 Million USD | -76.95% |
| 2013 FY | -4.27 Million USD | 83.05% |
| 2012 Q2 | -316 Thousand USD | -42.99% |
| 2012 Q1 | -221 Thousand USD | 91.31% |
| 2012 Q4 | -23.93 Million USD | -3066.53% |
| 2012 FY | -25.23 Million USD | -436.62% |
| 2012 Q3 | -756 Thousand USD | -139.24% |
| 2011 Q3 | 32 Thousand USD | 104.76% |
| 2011 Q2 | -672 Thousand USD | 55.79% |
| 2011 FY | -4.7 Million USD | -9.22% |
| 2011 Q4 | -2.54 Million USD | -8043.75% |
| 2011 Q1 | -1.52 Million USD | 40.95% |
| 2010 Q4 | -2.57 Million USD | -712.86% |
| 2010 Q1 | -1.69 Million USD | 93.44% |
| 2010 FY | -4.3 Million USD | 89.39% |
| 2010 Q2 | -821 Thousand USD | 51.42% |
| 2010 Q3 | 420 Thousand USD | 151.16% |
| 2009 Q1 | -5.57 Million USD | 67.62% |
| 2009 Q2 | -4.68 Million USD | 16.08% |
| 2009 FY | -40.57 Million USD | -11.39% |
| 2009 Q3 | -4.56 Million USD | 2.48% |
| 2009 Q4 | -25.74 Million USD | -463.91% |
| 2008 Q1 | -1.7 Million USD | 41.08% |
| 2008 Q4 | -17.23 Million USD | -79.69% |
| 2008 FY | -36.42 Million USD | -155.09% |
| 2008 Q3 | -9.58 Million USD | -21.38% |
| 2008 Q2 | -7.9 Million USD | -362.53% |
| 2007 Q2 | -3.88 Million USD | -73.29% |
| 2007 Q1 | -2.24 Million USD | -120.33% |
| 2007 FY | -14.28 Million USD | -341.5% |
| 2007 Q4 | -2.89 Million USD | 44.78% |
| 2007 Q3 | -5.25 Million USD | -35.07% |
| 2006 Q3 | -611 Thousand USD | -1751.35% |
| 2006 Q4 | -1.01 Million USD | -66.61% |
| 2006 Q2 | 37 Thousand USD | -99.53% |
| 2006 Q1 | 7.87 Million USD | 144.09% |
| 2006 FY | 5.91 Million USD | 121.99% |
| 2005 Q1 | -775 Thousand USD | -109.55% |
| 2005 Q2 | 4000.00 USD | 100.52% |
| 2005 Q3 | -8.25 Million USD | -206350.0% |
| 2005 Q4 | -17.86 Million USD | -116.56% |
| 2005 FY | -26.88 Million USD | -176.4% |
| 2004 Q1 | 9.8 Million USD | 31.77% |
| 2004 Q3 | 9.03 Million USD | 9.71% |
| 2004 FY | 35.19 Million USD | 79.64% |
| 2004 Q4 | 8.11 Million USD | -10.23% |
| 2004 Q2 | 8.23 Million USD | -16.05% |
| 2003 FY | 19.59 Million USD | 139.04% |
| 2003 Q2 | 4.54 Million USD | 326.29% |
| 2003 Q4 | 7.44 Million USD | 13.81% |
| 2003 Q3 | 6.54 Million USD | 44.07% |
| 2003 Q1 | 1.06 Million USD | 112.84% |
| 2002 Q4 | -8.29 Million USD | 63.07% |
| 2002 Q1 | -4.47 Million USD | -123.42% |
| 2002 Q2 | -14.93 Million USD | -233.45% |
| 2002 Q3 | -22.46 Million USD | -50.48% |
| 2002 FY | -50.17 Million USD | -494.92% |
| 2001 Q2 | 6.39 Million USD | -61.75% |
| 2001 Q4 | 19.12 Million USD | 164.77% |
| 2001 Q1 | 16.71 Million USD | -0.33% |
| 2001 Q3 | -29.52 Million USD | -561.84% |
| 2001 FY | 12.7 Million USD | -68.92% |
| 2000 FY | 40.87 Million USD | 160.36% |
| 2000 Q4 | 16.76 Million USD | 125.83% |
| 2000 Q3 | 7.42 Million USD | -6.2% |
| 2000 Q2 | 7.91 Million USD | -9.73% |
| 2000 Q1 | 8.76 Million USD | 56.58% |
| 1999 Q1 | 3.7 Million USD | 131.25% |
| 1999 Q2 | 4.1 Million USD | 10.81% |
| 1999 Q3 | 3 Million USD | -26.83% |
| 1999 FY | 15.7 Million USD | 70.65% |
| 1999 Q4 | 5.6 Million USD | 86.67% |
| 1998 Q2 | 1.2 Million USD | -82.61% |
| 1998 FY | 9.2 Million USD | 283.33% |
| 1998 Q3 | 1.5 Million USD | 25.0% |
| 1998 Q4 | 1.6 Million USD | 6.67% |
| 1998 Q1 | 6.9 Million USD | 118.45% |
| 1997 Q4 | -37.4 Million USD | -351.01% |
| 1997 Q2 | 14.9 Million USD | 49.0% |
| 1997 Q1 | 10 Million USD | 0.0% |
| 1997 FY | 2.4 Million USD | 0.0% |
| 1997 Q3 | 14.9 Million USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| American Bio Medica Corporation | -1.24 Million USD | 325.765% |
| Arrayit Corporation | -3.62 Million USD | 177.405% |
| Atlantic International Corp. | -5.73 Million USD | 148.914% |
| Biocept, Inc. | -31.98 Million USD | 108.767% |
| Bioqual, Inc. | -19.63 Thousand USD | 14378.44% |
| CardioGenics Holdings Inc | -772.14 Thousand USD | 463.146% |
| DermTech, Inc. | -103.73 Million USD | 102.703% |
| Global WholeHealth Partners Corporation | - USD | -Infinity% |
| Hangzhou Tigermed Consulting Co., Ltd. | 2.48 Billion USD | 99.887% |
| HTG Molecular Diagnostics, Inc. | -20.82 Million USD | 113.462% |
| iMD Companies, Inc. | -175.44 Thousand USD | 1698.213% |
| IDenta Corp. | -1499.00 USD | 187158.039% |
| Integrative Health Technologies, Inc. | 38.69 Thousand USD | -7147.351% |
| InVitro International | -25.33 Thousand USD | 11165.946% |
| Lumos Diagnostics Holdings Limited | -7.12 Million USD | 139.371% |
| Many Bright Ideas Technologies Inc. | -58.11 Thousand USD | 4925.165% |
| Medical Imaging Corp. | -819.48 Thousand USD | 442.168% |
| NovelStem International Corp. | -3.52 Million USD | 179.528% |
| Optigenex Inc. | 1.39 Million USD | -101.606% |
| PharmChem, Inc. | 973.14 Thousand USD | -188.137% |
| Proteome Sciences plc | -1.62 Million USD | 272.98% |
| Response Genetics, Inc | -21.37 Million USD | 113.117% |
| Rennova Health, Inc. | -1.4 Million USD | 298.931% |
| RushNet, Inc. | -684.7 Thousand USD | 509.519% |
| ScreenPro Security Inc. | -2.59 Million USD | 208.161% |
| Stella Diagnostics Inc. | -11.42 Million USD | 124.538% |
| StageZero Life Sciences Ltd. | -7.74 Million USD | 136.196% |
| Todos Medical Ltd. | -9.74 Million USD | 128.765% |